Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

出版年份 2020 全文链接

标题

作者

关键词

出版物

Volume 38, Issue 18_suppl, Pages LBA5-LBA5

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2020-06-01

DOI

10.1200/jco.2020.38.18_suppl.lba5

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now